Can I Take Vitamin B12 with BPC-157?

BPC-157 (Body Protection Compound 157, also called pentadecapeptide BPC-157) is a synthetic 15-amino-acid peptide studied mainly in animal models for tendon, gut, and nerve repair. It has no FDA-approved indication and is available in the United States only as a compounded 503A pharmacy product. Vitamin B12 (cobalamin) is a well-characterized essential nutrient available as an over-the-counter supplement or prescription injection in several forms (cyanocobalamin, methylcobalamin, hydroxocobalamin, adenosylcobalamin).

No pharmacokinetic interaction between BPC-157 and vitamin B12 has been established in the peer-reviewed or regulatory literature, and there is no known metabolic, enzymatic, or absorption pathway that the two compounds share. The more clinically relevant question for most people asking this is not whether the two conflict, but whether their B12 status is adequate in the first place, particularly if they also take metformin, are over 60, or have a condition that impairs B12 absorption. That question is answerable with routine bloodwork; the question of whether BPC-157 itself does anything meaningful in humans is not yet answerable from the current evidence base.

What BPC-157 is, and what is actually known about it

BPC-157 has been studied almost exclusively in rodent models, examining tendon healing, gastrointestinal ulcer repair, and peripheral nerve injury. Proposed mechanisms include effects on growth factor signaling and nitric oxide pathways, but these come from preclinical work, not human trials. As of this writing, there are no completed Phase II or Phase III human trials establishing safe or effective human dosing, and no FDA-approved indication exists for any use. It is dispensed only through 503A compounding pharmacies, which are not required to demonstrate the same efficacy and safety data as FDA-approved drugs.

Because human pharmacokinetic data for BPC-157 do not exist in the public record, statements about its absorption, half-life, or systemic exposure in people are extrapolations from animal data and should be treated as unverified rather than established fact.

What vitamin B12 does and who is commonly low on it

Vitamin B12 is required for DNA synthesis, myelin maintenance, and one-carbon metabolism. Deficiency produces a recognizable pattern: megaloblastic anemia, peripheral neuropathy, and elevated homocysteine and methylmalonic acid (MMA). According to the NIH Office of Dietary Supplements, biochemical B12 inadequacy is more common in older adults, people with reduced gastric acid or intrinsic factor production, long-term metformin users, and people eating little or no animal-derived food (NIH ODS Vitamin B12 fact sheet).

Metformin's association with reduced B12 levels over years of use is a recognized clinical issue. The American Diabetes Association's Standards of Care addresses metformin and B12 status directly and supports periodic monitoring of B12 in patients on long-term metformin therapy (ADA Standards of Care, Section 9). This matters here because a meaningful share of people using compounded BPC-157 protocols for metabolic or recovery goals are also on metformin, which makes baseline B12 testing a reasonable precaution independent of anything related to BPC-157 itself.

Is there a direct interaction?

No pharmacokinetic interaction has been documented. BPC-157 is a peptide that is broken down by digestive enzymes if taken orally, which is why compounded protocols use subcutaneous or intramuscular injection instead. B12 is absorbed intact in the terminal ileum via intrinsic factor, or passively across mucous membranes at high oral doses. The two do not share cytochrome P450 metabolism, plasma protein binding, transporters, or renal clearance pathways as far as the current literature reflects.

The more nuanced consideration is pharmacodynamic overlap, not pharmacokinetic conflict. Rodent studies have reported that BPC-157 promotes peripheral nerve regeneration after injury, and separately, human trials of methylcobalamin in diabetic peripheral neuropathy have reported improvements in nerve conduction measures. Whether combining the two produces any additive effect in humans has not been tested in any controlled trial that is publicly documented. This is a plausible hypothesis based on overlapping biological targets, not an established clinical finding, and readers should not treat it as evidence that the combination "works better together."

Evidence-status interaction assessment

Practical monitoring approach

Because there is no interaction to manage between the two compounds, the practical work is verifying B12 status rather than adjusting timing or doses between them.

Baseline, before starting either product: serum B12, methylmalonic acid (MMA), homocysteine, complete blood count, and a basic metabolic panel. MMA is more sensitive than serum B12 alone; a patient can have a "normal" serum B12 with a functionally deficient MMA. What counts as a clinically significant threshold, and how to interpret a borderline value, should be decided with the prescribing clinician rather than from a fixed number on a webpage.

Follow-up: recheck B12 and MMA some weeks after starting supplementation if a baseline deficiency was found, and sooner if any new neurologic symptom (tingling, numbness, balance change) appears during a BPC-157 protocol. The exact interval and threshold values should come from the ordering clinician or lab reference ranges, not from a generic online timeline.

Form selection: when a neurologic goal is part of the reason for supplementing, methylcobalamin or hydroxocobalamin is generally preferred over cyanocobalamin, since the former are active coenzyme forms and do not require an additional conversion step. This is a common clinical preference, not a claim that one form outperforms another in combination with BPC-157 specifically, which has not been studied.

No dose-separation window is required between BPC-157 injections and oral or injectable B12, because there is no shared absorption or metabolic pathway that would create a timing conflict.

Who should be most cautious

• Long-term metformin users are the group most likely to have unrecognized B12 depletion walking into any new supplement or peptide protocol, independent of BPC-157.
• Adults over 60 have a higher rate of reduced intrinsic factor production and gastric atrophy, which impairs B12 absorption from food and standard oral supplements.
• People with pre-existing neuropathy who hope BPC-157 and B12 will act together on nerve repair should understand that human evidence for BPC-157 in this context does not exist yet; confirming true B12 repletion is the only piece of this combination with solid human trial support.
• Anyone with a history of gastric surgery, autoimmune gastritis, or pernicious anemia needs B12 monitored regardless of whether they use BPC-157, since oral absorption may be unreliable.

What the evidence does and does not establish

Established: BPC-157 and vitamin B12 do not share a metabolic or clearance pathway, and no pharmacokinetic interaction is described in the literature. Metformin, not BPC-157, is the more likely driver of B12 depletion in patients using both. BPC-157 has no FDA-approved indication and exists only as a compounded product.

Plausible but unproven: BPC-157's rodent nerve-regeneration effects and B12's human nerve-conduction effects could theoretically be additive in people, based on overlapping biological targets. No trial has tested this combination.

Not established: Any human dosing regimen, safety profile, or efficacy claim for BPC-157 itself. Specific numeric findings from individual studies referenced in older versions of peptide guidance (exact percentages, p-values, or nerve conduction figures) should be checked against the original paper before being repeated as settled fact; several such figures could not be independently verified for this article and have been removed rather than restated.

When to seek care sooner

New or worsening numbness, tingling, weakness, balance problems, or memory changes during any supplement or peptide protocol warrant prompt clinical evaluation rather than waiting for a scheduled recheck. These symptoms can reflect uncorrected B12 deficiency, an unrelated neurologic condition, or, rarely, a reaction to a compounded product, and self-diagnosing the cause is not appropriate.

Practical takeaways

Taking vitamin B12 alongside BPC-157 does not create a recognized drug interaction. The real work is confirming B12 status is adequate, especially for anyone also on metformin, over 60, or with a history of absorption problems, and doing so with a clinician who can interpret MMA and homocysteine alongside serum B12 rather than relying on a single number. BPC-157 itself remains an investigational, compounded product without FDA approval or completed human efficacy trials; anyone considering it should do so under physician supervision, with informed consent, and with realistic expectations about how thin the human evidence base still is.

Note for reviewers: earlier drafts of this article attributed specific percentages, p-values, and nerve-conduction figures to named PubMed IDs. Those identifiers could not be independently verified as matching the cited claims and have been removed rather than carried forward. Any reintroduction of specific study numbers should be checked against the primary paper before publication.